Related references
Note: Only part of the references are listed.Macrophage targeting in cancer
Martha Lopez-Yrigoyen et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2021)
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma
Adam D. Cohen et al.
CLINICAL CANCER RESEARCH (2020)
Ixazomib Improves Bone Remodeling and Counteracts Sonic Hedgehog Signaling Inhibition Mediated by Myeloma Cells
Daniele Tibullo et al.
CANCERS (2020)
Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
Jort J. van der Schans et al.
FRONTIERS IN ONCOLOGY (2020)
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma
Oksana Zavidij et al.
NATURE CANCER (2020)
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
Yu-Tzu Tai et al.
LEUKEMIA (2019)
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome
Christina Hadjiaggelidou et al.
ANNALS OF HEMATOLOGY (2019)
Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation
Lisha Ai et al.
MOLECULAR CANCER (2019)
Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy
Ofrat Beyar-Katz et al.
MOLECULAR CANCER RESEARCH (2019)
Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo
Khatora S. Opperman et al.
NEOPLASIA (2019)
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
Alessandra Romano et al.
FRONTIERS IN ONCOLOGY (2019)
Onset of Regulatory B Cells Occurs at Initial Stage of B Cell Dysfunction in Multiple Myeloma
Zhongqing Zou et al.
BLOOD (2019)
Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells
Arghya Ray et al.
BLOOD (2019)
Macrophage functions in wound healing
Malgorzata Kloc et al.
JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE (2019)
Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy
Jithendra Kini Bailur et al.
JCI INSIGHT (2019)
High numbers of CD163+tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens
Hua Wang et al.
JOURNAL OF CANCER (2019)
TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma
Camille Guillerey et al.
BLOOD (2018)
Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment
Kyohei Nakamura et al.
CANCER CELL (2018)
Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy
Prajakta Shinde et al.
SCIENTIFIC REPORTS (2018)
A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
Wing Keung Chan et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma
Manh-Cuong Vo et al.
FRONTIERS IN IMMUNOLOGY (2018)
Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade
Simone A. Minnie et al.
BLOOD (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Increased activated regulatory T cell subsets and aging Treg-like cells in multiple myeloma and monoclonal gammopathy of undetermined significance: a case control study
Ji-nuo Wang et al.
CANCER CELL INTERNATIONAL (2018)
Antigen-mediated regulation in monoclonal gammopathies and myeloma
Shiny Nair et al.
JCI INSIGHT (2018)
Genomic complexity of multiple myeloma and its clinical implications
Salomon Manier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
S. K. Kumar et al.
LEUKEMIA (2017)
Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu
L. Zhang et al.
BLOOD CANCER JOURNAL (2017)
Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens
Adrien Bosseboeuf et al.
JCI INSIGHT (2017)
B cell regulation in cancer and anti-Xtumor immunity
Anushruti Sarvaria et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2017)
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
Bruno Paiva et al.
BLOOD (2016)
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities
G. Shay et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma
S. Panchabhai et al.
LEUKEMIA (2016)
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy
David J. Chung et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma
Alejandra Gutierrez-Gonzalez et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy
Indu R. Ramachandran et al.
CANCER LETTERS (2016)
Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma
Shiny Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma
Marilene Binsfeld et al.
ONCOTARGET (2016)
B cell regulation of the anti-tumor response and role in carcinogenesis
Marc Schwartz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy
Madhav V. Dhodapkar et al.
BLOOD (2015)
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing
Patrizia Leone et al.
BLOOD (2015)
Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma
Patricia Maiso et al.
CANCER RESEARCH (2015)
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
A. Ray et al.
LEUKEMIA (2015)
The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells
Jinheng Wang et al.
ONCOTARGET (2015)
Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma
Jeffrey Lee Jensen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Tumor-induced CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients
Zhitao Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Targeting the bone marrow microenvironment in multiple myeloma
Yawara Kawano et al.
IMMUNOLOGICAL REVIEWS (2015)
Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells
Jacqueline E. Noll et al.
HAEMATOLOGICA (2014)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
D. Atanackovic et al.
LEUKEMIA (2014)
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib
A. Ray et al.
LEUKEMIA (2014)
Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma
James Favaloro et al.
LEUKEMIA & LYMPHOMA (2014)
Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype
Katia Beider et al.
ONCOTARGET (2014)
Immunological Dysregulation in Multiple Myeloma Microenvironment
Alessandra Romano et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Tumor-associated macrophages as a prognostic parameter in multiple myeloma
Elif Suyani et al.
ANNALS OF HEMATOLOGY (2013)
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
Guellue Topal Goerguen et al.
BLOOD (2013)
Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation
Marco Tucci et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer
Xiaoqiang Tang
CANCER LETTERS (2013)
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
Roberto J. Pessoa de Magalhaes et al.
HAEMATOLOGICA (2013)
Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy
Regis T. Costello et al.
IMMUNOLOGY (2013)
Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in Bone Marrow
Indu R. Ramachandran et al.
JOURNAL OF IMMUNOLOGY (2013)
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
S. V. Rajkumar et al.
LEUKEMIA (2013)
Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance
C. Bryant et al.
BLOOD CANCER JOURNAL (2013)
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies
Ola Landgren
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines
I. Poschke et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
S100A9 a new marker for monocytic human myeloid-derived suppressor cells
Fei Zhao et al.
IMMUNOLOGY (2012)
Bone Marrow Microenvironment in Multiple Myeloma Progression
S. Manier et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow
E. Van Valckenborgh et al.
LEUKEMIA (2012)
The role of natural killer cells in immunity against multiple myeloma
James Godfrey et al.
LEUKEMIA & LYMPHOMA (2012)
Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent
Sylvia Feyler et al.
PLOS ONE (2012)
Functionally Suppressive CD8 T Regulatory Cells Are Increased in Patients with Multiple Myeloma: A Cause for Immune Impairment
Karthick Raja Muthu Raja et al.
PLOS ONE (2012)
Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells
Purevdorj B. Olkhanud et al.
CANCER RESEARCH (2011)
Mice Lacking Endogenous IL-10-Producing Regulatory B Cells Develop Exacerbated Disease and Present with an Increased Frequency of Th1/Th17 but a Decrease in Regulatory T Cells
Natalie A. Carter et al.
JOURNAL OF IMMUNOLOGY (2011)
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt et al.
JOURNAL OF IMMUNOTHERAPY (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma
Vito Racanelli et al.
BLOOD (2010)
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
Guellue Goerguen et al.
BLOOD (2010)
Natural killer cells and cancer: Regulation by the killer cell Ig-like receptors (KIR)
Amanda K. Purdy et al.
CANCER BIOLOGY & THERAPY (2010)
Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR-/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma
M. K. Brimnes et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2010)
Utilizing the FIV model to understand dendritic cell dysfunction and the potential role of dendritic cell immunization in HIV infection
Tracy L. Lehman et al.
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY (2010)
γδ T cell effector functions: a blend of innate programming and acquired plasticity
Marc Bonneville et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis
Yuhuan Zheng et al.
BLOOD (2009)
CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4-CD8-αβTCR+ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden
Sylvia Feyler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
Dharminder Chauhan et al.
CANCER CELL (2009)
Oncogenic stress sensed by the immune system: role of natural killer cell receptors
David H. Raulet et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
Kiavash Movahedi et al.
BLOOD (2008)
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
Masahisa Jinushi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells
Yasser M. El-Sherbiny et al.
CANCER RESEARCH (2007)
MyD88-dependent expansion of an immature GR-1+ CD11b+ population induces T cell suppression and Th2 polarization in sepsis
Matthew J. Delano et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients
Lotta Hansson et al.
CLINICAL CANCER RESEARCH (2007)
Clinical stage-depending decrease of NK cell activity in multiple myeloma patients
Vladimir Jurisic et al.
MEDICAL ONCOLOGY (2007)
Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells
Siqing Wang et al.
BLOOD (2006)
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Ichiro Hanamura et al.
BLOOD (2006)
Enhancement of clonogenicity of human multiple myeloma by dendritic cells
Anjli Kukreja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Inhibitory effects of B cells on antitumor immunity
Satoshi Inoue et al.
CANCER RESEARCH (2006)
Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma
MK Brimnes et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
Dysfunctional T regulatory cells in multiple myeloma
RH Prabhala et al.
BLOOD (2006)
Increased rejection of primary tumors in mice lacking B cells:: Inhibition of anti-tumor CTL and TH1 cytokine responses by B cells
S Shah et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated γδ lymphocytes
S Girlanda et al.
CANCER RESEARCH (2005)
Production of type I interferons: plasmacytoid dendritic cells and beyond
C Asselin-Paturel et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
E Carbone et al.
BLOOD (2005)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy
MV Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
γδ T cells for immune therapy of patients with lymphoid malignancies
M Wilhelm et al.
BLOOD (2003)
Anti-myeloma activity of natural killer lymphocytes
C Frohn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
M Ratta et al.
BLOOD (2002)
Activity of interleukin 6 in the differentiation of monocytes to macrophages and dendritic cells
H Mitani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Share Paper
